NASDAQ:BLPH Bellerophon Therapeutics (BLPH) Stock Forecast, Price & News $0.40 +0.02 (+5.30%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$0.38▼$0.4050-Day Range$0.38▼$0.7152-Week Range$0.37▼$12.58Volume22,279 shsAverage Volume986,100 shsMarket Capitalization$4.86 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Bellerophon Therapeutics MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside403.0% Upside$2.00 Price TargetShort InterestHealthy1.61% of Shares Sold ShortDividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews Sentiment0.48Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 stars 3.2 Analyst's Opinion Consensus RatingBellerophon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.00, Bellerophon Therapeutics has a forecasted upside of 403.0% from its current price of $0.40.Amount of Analyst CoverageBellerophon Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.61% of the outstanding shares of Bellerophon Therapeutics have been sold short.Short Interest Ratio / Days to CoverBellerophon Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bellerophon Therapeutics has recently increased by 59.79%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBellerophon Therapeutics does not currently pay a dividend.Dividend GrowthBellerophon Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBellerophon Therapeutics has received a 77.00% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for pulmonary hearth diseases" and "Clinical research services for hypertension" products. See details.Environmental SustainabilityThe Environmental Impact score for Bellerophon Therapeutics is -0.86. Previous Next 1.9 News and Social Media Coverage News SentimentBellerophon Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Bellerophon Therapeutics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bellerophon Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders23.30% of the stock of Bellerophon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.88% of the stock of Bellerophon Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Bellerophon Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bellerophon Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBellerophon Therapeutics has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bellerophon Therapeutics (NASDAQ:BLPH) StockBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Read More BLPH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLPH Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comBellerophon Therapeutics, Inc. (NASDAQ:BLPH) Sees Significant Increase in Short InterestSeptember 27, 2023 | americanbankingnews.comBellerophon Therapeutics (NASDAQ:BLPH) Earns Hold Rating from Analysts at StockNews.comSeptember 30, 2023 | Legacy Research (Ad)ATTENTION: Digital Dollar Could Send this $0.25 Play SkyrocketingIn just a few days, the U.S. government could announce this mandatory recall on the U.S. dollar… And replace it with a new digital dollar. And that could send this $0.25 alternative investment skyrocketing.August 8, 2023 | finance.yahoo.comBLPH - Bellerophon Therapeutics, Inc.July 25, 2023 | msn.comWhat's Happening With Bellerophon Therapeutics Stock Today?July 25, 2023 | investorplace.comWhy Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?July 6, 2023 | msn.comBellerophon Therapeutics (BLPH) Price Target Decreased by 92.23% to 2.04June 6, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Bellerophon TherapeuticsSeptember 30, 2023 | The Oxford Club (Ad)He's Giving Away His Ultimate Dividend Package FOR FREE!Marc Lichtenfeld, Author of Get Rich with Dividends, is giving away his Ultimate Dividend Package, Including Details on His #1 Dividend Stock... the Safest 8% Dividend in the World... the Top Three "Extreme Dividend" Stocks... and Much, Much More. For Free. June 6, 2023 | finance.yahoo.comIs Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?June 6, 2023 | msn.comLaidlaw & Co. Downgrades Bellerophon Therapeutics (BLPH)June 6, 2023 | msn.comHC Wainwright & Co. Maintains Bellerophon Therapeutics (BLPH) Buy RecommendationJune 5, 2023 | msn.comBellerophon Therapeutics Stock Nosedive: Here's WhyJune 5, 2023 | msn.comWhy Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today?June 5, 2023 | finance.yahoo.comBellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung DiseaseMay 19, 2023 | msn.comLucy Scientific, Bioventus top healthcare gainers; Enveric, Elevation among losersMay 17, 2023 | finance.yahoo.comBellerophon Therapeutics (NASDAQ:BLPH) delivers shareholders fantastic 978% return over 1 year, surging 18% in the last week aloneMay 16, 2023 | finanznachrichten.deBellerophon Therapeutics, Inc.: Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial ResultsMay 15, 2023 | finance.yahoo.comBellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comBellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseApril 28, 2023 | finance.yahoo.comBellerophon Therapeutics (BLPH) Outpaces Stock Market Gains: What You Should KnowApril 24, 2023 | finance.yahoo.comBellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?April 19, 2023 | finance.yahoo.comBellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should KnowApril 13, 2023 | msn.comBellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should KnowApril 4, 2023 | msn.comHC Wainwright & Co. Reiterates Bellerophon Therapeutics (BLPH) Buy RecommendationApril 4, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Bellerophon (BLPH)April 3, 2023 | finance.yahoo.comWhen Will Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Turn A Profit?See More Headlines Receive BLPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BLPH Company Calendar Last Earnings8/14/2023Today9/30/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLPH CUSIPN/A CIK1600132 Webwww.bellerophon.com Phone(908) 574-4770FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.00 High Stock Price Forecast$2.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+403.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,830,000.00 Net MarginsN/A Pretax Margin-242.52% Return on Equity-208.93% Return on Assets-114.57% Debt Debt-to-Equity RatioN/A Current Ratio2.00 Quick Ratio2.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book1.47Miscellaneous Outstanding Shares12,230,000Free Float9,383,000Market Cap$4.86 million OptionableNot Optionable Beta0.64 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Parag Suresh Shah (Age 46)VP of Bus. Operations Comp: $396.82kKey CompetitorsTempest TherapeuticsNASDAQ:TPSTGRI BioNASDAQ:GRIJaguar HealthNASDAQ:JAGXHoth TherapeuticsNASDAQ:HOTHEnveric BiosciencesNASDAQ:ENVBView All CompetitorsInsiders & InstitutionsBlackRock Inc.Bought 33,527 shares on 8/11/2023Ownership: 1.243%Renaissance Technologies LLCSold 92,600 shares on 8/11/2023Ownership: 0.740%Acadian Asset Management LLCBought 265,253 shares on 8/7/2023Ownership: 2.538%Life Science Opportu PuissanceSold 134,421 sharesTotal: $111,569.43 ($0.83/share)Life Science Opportu PuissanceSold 560,000 sharesTotal: $5.30 M ($9.46/share)View All Insider TransactionsView All Institutional Transactions BLPH Stock - Frequently Asked Questions Should I buy or sell Bellerophon Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLPH, but not buy additional shares or sell existing shares. View BLPH analyst ratings or view top-rated stocks. What is Bellerophon Therapeutics' stock price forecast for 2023? 3 Wall Street analysts have issued 1-year price targets for Bellerophon Therapeutics' stock. Their BLPH share price forecasts range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 403.0% from the stock's current price. View analysts price targets for BLPH or view top-rated stocks among Wall Street analysts. How have BLPH shares performed in 2023? Bellerophon Therapeutics' stock was trading at $0.90 at the beginning of the year. Since then, BLPH shares have decreased by 55.8% and is now trading at $0.3976. View the best growth stocks for 2023 here. Are investors shorting Bellerophon Therapeutics? Bellerophon Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 197,500 shares, an increase of 59.8% from the August 31st total of 123,600 shares. Based on an average daily volume of 193,800 shares, the short-interest ratio is presently 1.0 days. View Bellerophon Therapeutics' Short Interest. When is Bellerophon Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our BLPH earnings forecast. How were Bellerophon Therapeutics' earnings last quarter? Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) released its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.42) earnings per share for the quarter. When did Bellerophon Therapeutics' stock split? Bellerophon Therapeutics's stock reverse split on the morning of Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Bellerophon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX). When did Bellerophon Therapeutics IPO? (BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers. What is Bellerophon Therapeutics' stock symbol? Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH." How do I buy shares of Bellerophon Therapeutics? Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bellerophon Therapeutics' stock price today? One share of BLPH stock can currently be purchased for approximately $0.40. How much money does Bellerophon Therapeutics make? Bellerophon Therapeutics (NASDAQ:BLPH) has a market capitalization of $4.86 million. The biotechnology company earns $-19,830,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. How can I contact Bellerophon Therapeutics? Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The official website for the company is www.bellerophon.com. The biotechnology company can be reached via phone at (908) 574-4770 or via email at btinvestorrelations@bellerophon.com. This page (NASDAQ:BLPH) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellerophon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.